Patrick Fabbio has been appointed Chief Financial Officer of electroCore, the US based electroceutical healthcare company. Pat, who was previously VP Finance for NPS Pharmaceuticals, has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies.
During his three years with NPS, he led the build-out of the global finance department and supported the $5.2 billion sale to Shire plc in February 2015. Prior to NPS, Pat served in senior financial positions including VP Finance, Catalent Pharma Solutions, CFO of Ikano Therapeutics, and senior corporate finance, commercial and transactional roles at Sanofi as well as Corporate Controller for Biomatrix Inc.
ElectroCore founder and CEO JP Errico commented "I am delighted that Pat has joined the electroCore team. Pat is a senior executive with broad experience in general management and finance. He has a strong track record of success in corporate finance in the healthcare sector.”
Pat graduated from Pace University with a BBA in Accounting and from the Stern School of Business at New York University, with a Master’s Degree in Finance. He has received his certified public accountant license in New Jersey.
electroCore LLC, is focused on developing non-invasive vagus nerve stimulation therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology, and respiratory fields. The company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic co-morbidities of gastric motility, psychiatric, sleep, and pain disorders that drive disproportionately large direct and indirect costs within the healthcare system and society. For more information please visit www.electrocoremedical.com.
Image Credit: electroCore